tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

PALI Stock Latest News

Palisade Bio Reports Improved Quarterly Losses
Company AnnouncementsPalisade Bio Reports Improved Quarterly Losses
8h ago
PALI
Buy Rating for Palisade Bio: Promising Phase 1a Trial Results and Strategic Focus on Unmet Needs in Crohn’s Disease
PremiumRatings
Buy Rating for Palisade Bio: Promising Phase 1a Trial Results and Strategic Focus on Unmet Needs in Crohn’s Disease
4d ago
PALI
Palisade Bio files to sell 13.14M shares of common stock, warrants
PremiumThe Fly
Palisade Bio files to sell 13.14M shares of common stock, warrants
7d ago
PALI
Palisade Bio reports Phase 1a results for PALI-2108
PremiumThe Fly
Palisade Bio reports Phase 1a results for PALI-2108
7d ago
PALI
Palisade Bio’s PALI-2108: Promising Phase 1 Results and Strategic Positioning Drive Buy Rating
PremiumRatings
Palisade Bio’s PALI-2108: Promising Phase 1 Results and Strategic Positioning Drive Buy Rating
18d ago
PALI
Palisade Bio presents preclinical data on PALI-2108
PremiumThe FlyPalisade Bio presents preclinical data on PALI-2108
28d ago
PALI
Palisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108
Premium
The Fly
Palisade completes dosing in Phase 1b portion of Phase 1a/1n study of PALI-2108
2M ago
PALI
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
3M ago
ALT
CLLS
Palisade Bio commences dosing in first UC patient cohort in study of PALI-2108
PremiumThe Fly
Palisade Bio commences dosing in first UC patient cohort in study of PALI-2108
3M ago
PALI
PALI Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
PALI Upcoming Earnings Report: What to Expect?
3M ago
PALI
Palisade Bio receives cash proceeds from Canada’s SR&ED tax incentive program
PremiumThe Fly
Palisade Bio receives cash proceeds from Canada’s SR&ED tax incentive program
3M ago
PALI
Palisade Bio presents preclinical data of PALI-2108
PremiumThe Fly
Palisade Bio presents preclinical data of PALI-2108
4M ago
PALI
Palisade Bio completes all five SAD cohorts, advanced MAD cohorts for PALI-2108
PremiumThe FlyPalisade Bio completes all five SAD cohorts, advanced MAD cohorts for PALI-2108
5M ago
PALI
Palisade Bio appoints Feagan to Clinical Advisory Board
Premium
The Fly
Palisade Bio appoints Feagan to Clinical Advisory Board
6M ago
PALI
Palisade Bio announces preliminary results from Phase 1 study of PALI-2108
Premium
The Fly
Palisade Bio announces preliminary results from Phase 1 study of PALI-2108
6M ago
PALI
Palisade Bio to present preclinical results for PALI-2108
PremiumThe Fly
Palisade Bio to present preclinical results for PALI-2108
6M ago
PALI
Palisade Bio initiated with a Buy at Brookline
PremiumThe Fly
Palisade Bio initiated with a Buy at Brookline
6M ago
PALI
Palisade Bio price target lowered to $8 from $22.50 at Maxim
PremiumThe Fly
Palisade Bio price target lowered to $8 from $22.50 at Maxim
7M ago
PALI
Palisade Bio reports Q3 EPS ($2.32) vs. ($7.38) last year
PremiumThe Fly
Palisade Bio reports Q3 EPS ($2.32) vs. ($7.38) last year
7M ago
PALI
Palisade Bio expects cash to fund operations through 1Q25
PremiumThe FlyPalisade Bio expects cash to fund operations through 1Q25
7M ago
PALI
Palisade Bio announces first subject dosed in Phase 1 study of PALI-2108
Premium
The Fly
Palisade Bio announces first subject dosed in Phase 1 study of PALI-2108
7M ago
PALI
Palisade Bio announces data from two ex vivo studies of PALI-2108
Premium
The Fly
Palisade Bio announces data from two ex vivo studies of PALI-2108
7M ago
PALI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >